TP53-Mutated AML and Treatment Outcomes in the Era of Hypomethylating Agent/Venetoclax Therapy

Presenter Information

• D. Mueller MD
• S. Santhosh
• A. Singhal MD
• D. W. Chitty DO
• D. E. Gladstone MD
• B. Goldberg MD
• E. Jou MD
• J. E. Kolitz MD

Author ORCID Identifier(s)

0000-0002-3851-2672

Facility

NS/LIJ

Department

Division of Hematology/Oncology, Department of Medicine

Status

Fellow

Category

Event

Start Date

3-6-2026 11:30 AM